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Background/aim: The aim of this study was to determine the diagnostic performance of endobronchial ultrasound-guided transbronchial
needle aspiration (EBUS-TBNA) in the diagnosis of mediastinal and hilar lymph nodes (LNs) in patients with known extrapulmonary
malignancy.
Materials and methods: Between March 2011 and August 2013, 378 EBUS-TBNA procedures were performed. Sixty-three (16.6%) of
these were performed on known extrapulmonary malignancy patients.
Results: There were 28 male and 35 female patients, with median ages of 65 years (min–max: 53–87) and 57 years (min–max: 39–76),
respectively. From the 63 cases, 138 lymph nodes (LNs) were sampled with EBUS-TBNA (median: 2 LNs/patient; min–max: 1–4).
Results of EBUS-TBNA revealed malignancy in 18 (28.5%) and nonmalignancy in 45 (71.5%). In the nonmalignant group, there were
false negatives in 5 (7.9%), anthracosis in 13 (20.6%), reactive adenitis in 16 (25.3%), sarcoidosis in 7 (11.1%), and tuberculosis in 2
(3.1%), and 2 were not evaluated (lost to follow-up) (3.1%). The diagnostic sensitivity, accuracy, and negative predictive value of EBUSTBNA per patient were 78.2%, 91.8%, and 88.3%, respectively.
Conclusion: EBUS-TBNA is a safe, minimally invasive, and effective method and can be considered as the initial test for the
histopathological diagnosis of mediastinal and hilar lymphadenopathy in patients with extrapulmonary malignancy.
Key words: Endobronchial ultrasound-guided transbronchial needle aspiration, extrapulmonary malignancy, lymph node, mediastinum,
metastasis

1. Introduction
Endobronchial ultrasound-guided transbronchial needle
aspiration (EBUS-TBNA) is a minimally invasive and safe
procedure that allows the bronchoscopist to see beyond
the airway and to evaluate the diagnostic possibilities for
mediastinal and hilar pathology. There are many reports
confirming the diagnostic accuracy and safety of EBUSTBNA for nodal staging of nonsmall-cell lung cancer
(1–5). Mediastinal and hilar lymphadenopathy do not
always result from cancer; granulomatous diseases and
pneumoconiosis can be the causes of mediastinal or hilar
lymphadenopathy (6). The diagnosis of mediastinal and
hilar lymphadenopathy is important for the prognosis and
further treatment plan in patients with extrapulmonary
malignancy. Therefore, histopathological confirmation of
mediastinal lymphadenopathy is required.
Imaging studies, including computed tomography (CT)
and positron emission tomography (PET), are currently
available for detection of mediastinal metastases. However,
these modalities are often regarded as insufficient for making
* Correspondence: drceydaanar@hotmail.com
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a clinical decision because they do not allow pathologic
confirmation (4,7). Invasive procedures may be needed for a
definitive diagnosis. Although mediastinoscopy remains the
gold standard for evaluation of the mediastinum, it requires
general anesthesia and is associated with higher morbidity
and mortality, in addition to the fact that it cannot be used
to evaluate the hilar lymph nodes.
Recently, the utility of EBUS-TBNA for the evaluation
of mediastinal lymphadenopathy in lung cancer staging
(1–5), sarcoidosis (8–10), tuberculosis (11,12), or
lymphoma (13,14) has been reported. However, the role
of EBUS-TBNA in the diagnosis of mediastinal or hilar
metastasis from extrapulmonary malignancy has not been
well established, despite the results of recent studies (15–
19). Therefore, our primary endpoint was to determine the
etiology and prevalence of malignancy for hypermetabolic
or enlarged hilar/mediastinal lymph nodes (LNs) in
patients with a previously diagnosed extrapulmonary
malignancy during the oncologic follow-up period, and
the diagnostic yield of EBUS-TBNA in these LNs.
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2. Materials and methods
2.1. Patients
This retrospective study was conducted in a tertiary
hospital located in İzmir, which has a surface area of 12,000
km2 and a population of approximately 4 million, between
March 2011 and August 2013. Over the study period, a total
of 378 patients underwent EBUS-TBNA for the staging
and diagnosis of primary lung cancer, extrapulmonary
malignancy, tuberculosis lymphadenitis, sarcoidosis,
and a variety of clinical indications. Sixty-three patients
with proven or suspicious extrapulmonary malignancy
who underwent EBUS-TBNA for the diagnosis of nodal
metastasis were included in the study.
Demographic data, sites of primary malignancies,
radiological and PET-CT findings, EBUS findings, stations
of aspirated LNs, cytological and histological findings
and diagnoses, final diagnoses, and procedure-related
complications were recorded. Informed consent was
obtained from all patients for procedures and the use of
medical records.
2.2. Radiological evaluation
The indication of EBUS-TBNA in enrolled patients was
a LN with a short-axis diameter of >10 mm on thoracic
CT and/or LN with 18-fluorodeoxyglucose (FDG) uptake.
Patients had PET-CT scans as a part of their routine
oncological evaluation. The FDG PET-CT was considered
positive if the PET-CT report stated that there was
hypermetabolic activity with a standardized uptake value
of ≥2.5, consistent with malignant disease.
2.3. The EBUS-TBNA procedure
All EBUS-TBNA procedures were performed by the
same bronchoscopist. The EBUS-TBNA procedure was
performed by an EBUS-guided TBNA bronchoscope (7.5
MHz, BF-UC160F; Olympus Optical Co., Tokyo, Japan)
through the oral route, in the supine position under local
anesthesia with lidocaine and conscious sedation with
intravenous midazolam. Heart rate and oxygen saturation
of all patients were monitored during the procedure. An
examination of all mediastinal and hilar lymph node
stations accessible by EBUS were performed prior to the
TBNA procedure. The lymph node station was determined
according to the new international lymph node map
proposed by the International Association for the Study of
Lung Cancer (20).
If more than one node was detected, the decision of
which node to puncture depended on the physician’s
judgment based on findings from the CT and/or PET/
CT scans. Each target nodal station was punctured at least
twice, and one or more tissue core specimens were obtained
with a dedicated 22-gauge needle (NA-201SX-4022,
Olympus). The aspirate was then blown onto a glass slide
by pushing air using a 20-mL syringe. Aspirated material

was also obtained for cell block and mycobacterial cultures.
If no tissue core specimen was obtainable from the initial 2
aspirations, 3 or more aspirations of the lymph node were
performed until enough tissue core was obtained.
Serious complications such as respiratory failure,
bleeding
requiring
transfusion,
pneumothorax,
pneumomediastinum, or any minor complication such as
oxygen desaturation or arrhythmia during the procedure
were evaluated.
2.4. Pathological examination
Some amount of the aspirate was smeared onto glass slides,
air-dried, fixed immediately with 95% alcohol, and stained
with hematoxylin and eosin (H&E). The rest of the aspirate
was placed into a mixture of formalin and alcohol in order
to obtain a cell block for histological examination. Rapid
on-site cytological examination was not available.
2.5. Mycobacterial cultivation and identification
Fine-needle aspiration biopsy specimens obtained from
patients and placed in sterile tubes were transported to the
microbiology laboratory immediately. In the laboratory,
the samples were suspended in 1 mL of Middlebrook
7H9 medium and vortexed. The suspensions were then
digested and decontaminated by using a commercial
decontamination kit, Mycoprosafe (Salubris AS, İstanbul,
Turkey). Mycobacterial cultivation was performed by
MGIT 960 system (BD Biosciences, Sparks, MD, USA)
according to the recommendations of the manufacturer
as described elsewhere (21), and in Lowenstein–Jensen
slants (Salubris AS). An acid-fast smear preparation by
fluorochrome and/or Kinyoun staining was also applied to
each processed specimen. Differentiation of Mycobacterium
tuberculosis and nontuberculous mycobacteria was
performed by conventional methods (22) and BD
immunochromatographic test (BD Biosciences, Sparks,
MD, USA). M. tuberculosis H37Ra was used as the control
strain in all methods.
2.6. Final diagnosis
2.6.1. Malignancy
EBUS-TBNA results were considered malignant when
the aspirated material contained malignant cells. Tumorpositive findings from the EBUS-TBNA samples were not
surgically validated.
2.6.2. Granulomatous inflammation
A final diagnosis of sarcoidosis was made in the presence
of all of the following criteria: 1) consistent clinical and
radiological presentation; 2) demonstration of necrotizing
or nonnecrotizing granulomas on EBUS with negative
acid-fast bacilli and no growth of mycobacteria on culture;
3) clinical and radiological response after treatment with
glucocorticoids or spontaneous remission.
Diagnosis of tuberculosis was based on demonstration
of all of the following: granulomatous inflammation
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and the presence of acid-fast bacilli on microscopy, or a
positive culture for M. tuberculosis and clinico-radiological
response to antituberculosis treatment.
2.6.3. Anthracotic adenitis
When the presence of compact anthracotic pigment was
evaluated by the pathologists during the microscopic
examination of aspiration and histological specimens, the
LN was accepted as showing anthracotic adenitis.
2.6.4. Reactive adenitis
When the presence of lymphocytes, macrophages,
and immunoblasts and no presence of malignant cells,
granulomatous inflammation, compact anthracotic
pigment, or abundant epithelia cells were evaluated by the
pathologists in the microscopic examination of aspiration
and histological specimens, the LN was accepted as
showing reactive adenitis.
2.6.5. Follow-up
Any diagnosis other than malignancy required further
investigation, such as mediastinoscopy or thoracoscopy,
or radiologic follow-up on the outcome of the LNs for at
least 6 months. At the end of the follow-up period, the LNs
that were diagnosed as showing sarcoidosis, tuberculosis,
reactive adenitis, or anthracotic adenitis by EBUS-TBNA
and were stationary, decreased in size, or disappeared were
considered benign.
2.7. Statistical analysis
The statistical analyses were performed using SPSS 20. Data
were presented as medians and interquartile ranges (IQRs,
25th and 75th percentiles) for continuous variables and
as numbers and percentages for categorical variables. The
diagnostic sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), and accuracy
of EBUS-TBNA and PET-CT scan were calculated by
standard definitions.
3. Results
3.1. Patient characteristics
All 63 patients (28 male, 35 female) successfully
underwent EBUS-TBNA. The median ages of the male
and female patients were 65 years (min–max: 53–87)
and 57 years (min–max: 39–76), respectively. The most
common extrapulmonary malignancies observed were
genitourinary carcinoma (26.9%), followed by breast
carcinoma (23.8%), gastrointestinal malignancy (23. 8%),
and head and neck cancer (17.4%) (Table 1).
3.2. Details related to mediastinal and hilar lymph nodes
All patients had thoracic CT, and 54 patients had PETCT. One hundred and twenty LNs were hypermetabolic
on PET-CT. The frequencies of hilar and mediastinal LNs
assessed by EBUS-TBNA are shown in Table 2. A total of
138 LNs were sampled. The median number of LN stations
sampled per patient was 2 (IQR: 2–3). The median short-
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Table 1. Data for the 63 patients with extrapulmonary malignancy.
Malignancy

N

%

Breast carcinoma

15

23.8

Head and neck cancer

11

17.4

Laryngeal carcinoma
Salivary gland cancer
Nasopharynx carcinoma
Thyroid carcinoma

5
3
2
1

7.9
4.7
3.1
1.5

Genitourinary malignancy

17

26.9

Ovarian carcinoma
Endometrial carcinoma
Prostate cancer
Renal cell carcinoma
Bladder carcinoma
Adrenal liposarcoma

4
4
2
5
1
1

6.3
6.3
3.1
7.9
1.5
1.5

Gastrointestinal malignancy

15

23.8

Gastric carcinoma
Esophageal cancer
Pancreatic carcinoma
Colon
Rectum

6
1
2
2
4

9.5
1.5
3.1
3.1
6.3

Others

5

7.9

Skin
Melanoma
Conjunctiva
Chronic lymphocytic leukemia

1
1
1
2

1.5
1.5
1.5
3.1

Table 2. The frequency of the lymph nodes sampled by EBUSTBNA.
Lymph node

N (%)

Upper paratracheal lymph node

15 (10.8)

2R
2L

13 (9.4)
2 (1.4)

Lower paratracheal lymph node

43 (31.1)

4R
4L

32 (23.1)
11 (7.9)

Subcarinal lymph node (7)

43 (31.1)

Hilar or interlobar lymph node

37 (26.8)

10R
10L
11R
11L

3 (2.1)
3 (2.1)
17 (12.3)
14 (10.1)

R: Right, L: Left.
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axis of aspirated mediastinal LNs was 15 mm (IQR: 10–20
mm). In terms of stations, only hilar (stations 10 or 11)
nodes in 3 (4.7%) patients, only mediastinal (stations
2, 4, 7) nodes in 29 (46%) patients, and both hilar and
mediastinal nodes in 31 (49.2%) patients were sampled.
3.3. Final diagnostic results
In 18 (28.5%) patients, EBUS-TBNA confirmed metastasis
of extrapulmonary malignancy. The EBUS-TBNA results
of the remaining 45 cases were reactive lymph adenitis (n =
19), anthracotic lymph adenitis (n = 16), or granulomatous
inflammation (n = 10). Mediastinoscopy was performed
in 20 of 45 patients. Mediastinal lymph node metastasis
(n = 5), reactive adenitis (n = 9), anthracotic lymph node
(n = 5), and granulomatous inflammation (n = 1; final
diagnosis: sarcoidosis) were diagnosed in patients who
underwent mediastinoscopy. The results of false-negative
EBUS were 2 anthracosis and 3 reactive lymphadenitis.
The extrapulmonary malignancy of these 5 patients
were breast cancer, ovarian cancer, laryngeal cancer,
endometrial cancer, and parotid cancer.

The diagnostic algorithm for patients with suspected
mediastinal and/or hilar metastasis from extrapulmonary
malignancy is shown in the Figure. Two patients with
nonmalignant EBUS-TBNA results were lost to followup. Fifteen patients with a cytological diagnosis of reactive
lymph node or anthracosis were followed for a median of
10 (min–max: 6–12) months. Radiological LNs were stable
during this period, and these LNs were accepted as the
benign results of the EBUS-TBNA procedure.
Of 63 patients, the diagnoses were 23 malignancy
(36.5%), 16 reactive lymph adenitis (25.3%), 13 anthracosis
(20.6%), 7 sarcoidosis (11.1%), 2 tuberculosis (6.6%), and
2 lost to follow-up. EBUS-TBNA cultures were positive in
2 of the tuberculosis patients. The other 61 patients had a
negative culture for M. tuberculosis.
3.4. Diagnostic performances
Fifty-four patients had PET-CT and they had 120 LNs on
PET-CT. Of 54 patients, the diagnosis were 20 malignancy
(37%), 14 reactive lymph adenitis (25.9%), 12 anthracosis
(22.2%), 6 sarcoidosis (11.1%), and 2 tuberculosis (3.7%).

Mediastinal or hilar LNs in extrapulmonary
malignancy (n:63)

EBUS-TBNA: is result malignant ?
No (n: 45)

Yes (n:18)

Anthracotic (n:16)
Reactive Adenitis (n:19)
Granulomatous inﬂammation (n :10)

Total malignancy (n:23)
Was mediastinoscopy performed?
False negative results from EBUS-TBNA (n:5)

No (n:25)

Yes (n:20)

Anthracotic (n:5)
Reactive adenitis (n:9)
Granulomatous inﬂammation (n:1)

Clinical, radiological follow up.

Reactive
(n:7)

Anthracotic
(n:8)

Sarcoidosis
(n:6)

Tuberculosis
(n:2)

Lost to
follow up
(n:2)

Total benign (n:38)
Figure. Diagnostic algorithm for patients with suspected mediastinal and/or hilar metastasis from extrapulmonary malignancy.
LNs: lymph nodes; EBUS-TBNA: endobronchial ultrasound-guided transbronchial needle aspiration.
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The diagnostic sensitivity, specificity, PPV, NPV, and
accuracy of PET-CT per patient were 85%, 29.4%, 42.8%,
83.3%, and 51.8%, respectively. The diagnostic sensitivity,
specificity, PPV, NPV, and accuracy of EBUS-TBNA
per patient were 78.2%, 100%, 100%, 88.3%, and 91.8%,
respectively (Table 3).
3.5. Complications
Procedure-related complications were minor bleeding in
1 case and slight reversible oxygen desaturation in 1 case.
No other serious complications such as pneumothorax or
respiratory failure were observed.
4. Discussion
The present study showed that EBUS-TBNA is a sensitive,
accurate, minimally invasive, and safe procedure for the
evaluation of nodal metastases from extrapulmonary
malignancy. EBUS-TBNA demonstrated a sensitivity
of 78.2% with an overall diagnostic accuracy of 91.8%;
therefore, it is an important alternative to other techniques
for the diagnosis of intrathoracic lymphadenopathy in
patients with extrapulmonary malignancy.
In particular, the detection of enlarged mediastinal
lymphadenopathy in patients with extrapulmonary
malignancy is important for the planning of further
treatment. Although mediastinoscopy is considered the
gold standard diagnostic technique, it is associated with
risks due to general anesthesia, a serious complication rate
of 1%, and increased healthcare costs when compared with
minimally invasive techniques. Moreover, it is limited in
accessing the aortopulmonary window and posterior
subcarinal and hilar regions.
On the other hand, EBUS-TBNA is an established
procedure for sampling mediastinal lymph nodes and
is a minimally invasive technique. Earlier studies in
mediastinal staging or restaging of nonsmall-cell lung
cancer showed high diagnostic rates for EBUS-TBNA,

with sensitivity and PPVs of more than 90% and specificity
of 100% (3,23,24). Recently, EBUS-TBNA was performed
to evaluate intrathoracic lymphadenopathy in patients
with extrapulmonary malignancy. A large study of 161
suspected metastases from extrapulmonary malignancy
patients undergoing EBUS-TBNA demonstrated a
sensitivity rate of 87% (20). Other studies also showed a
sensitivity rate of 85%–96.3% (15–18) (Table 4). In the
present study, the sensitivity of EBUS-TBNA in suspected
metastases from extrapulmonary malignancy patients was
78.2%, which is lower than in other studies. This is because
the 3 patients who produced false negative results from
EBUS-TBNA were among the first 100 patients. This result
may be related to the level of experience of the person
who performed EBUS-TBNA. The European Respiratory
Society and American Thoracic Society Joint Statement
on Interventional Pulmonology states that trainees should
perform at least 40 procedures in a supervised setting,
and 25 procedures should be done annually to maintain
competency. The authors think that the clinician’s
experience of conventional TBNA seems to be a factor in
the EBUS learning period (25). Bizekis et al. found that
diagnostic accuracy was better in the last 26 patients than
in the first 25 patients. Hence, according to their study, the
lowest number of repetitions to learn the procedure was
approximately 50 (26).
Moreover, rapid on-site evaluation was not available in
our study. Additionally, NPV was 88.3% in this study, which
was similar to the results of other studies that reported rates
of between 76% and 86.9% (17,19,27,28). Five cases were
diagnosed as malignancy after mediastinoscopy, although
EBUS-TBNA results were reported as benign. Therefore,
the negative results by EBUS-TBNA should be verified
by surgical methods if the probability of malignancy is
different from clinical and radiological results.

Table 3. Diagnostic performances of F-18 fluorodeoxyglucose positron emission
tomography/computed tomography and endobronchial ultrasound-guided
transbronchial needle aspiration.
Per patient basis

PET-CT
%

EBUS-TBNA
%

Sensitivity

85

78.2%

Specificity

29.4

100%

Positive predictive value

42.8

100%

Negative predictive value

83.3

88.3%

Diagnostic accuracy

51.8

91.8%

PET-CT: Fluorodeoxyglucose positron emission tomography/computed tomography.
EBUS-TBNA: Endobronchial ultrasound-guided transbronchial needle aspiration.
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Table 4. Diagnostic performances in the literature and our results.
Study/country

No. of patients

Sensitivity

Specificity

NPV

Accuracy

Song et al., 2011 (17), Korea

56

88%

-

85%

93%

Park et al., 2011 (15), Korea

59

81%

100%

-

-

Navani et al., 2011 (19), UK

161

87%

-

73%

88%

Tournoy et al., 2011 (18), Belgium

92

85%

-

76%

-

Parmaksiz et al., 2012 (27), Turkey

48

89.2%

100%

86.9%

93.7%

Özgül et al., 2013 (16), Turkey

40

90%

100%

90.9%

95%

Sanz-Santos et al., 2013 (28), Spain
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86.4%

-

75%

90.3%

Our study, 2014, Turkey

63

78.2%

100%

88.3%

91.8%

NPV: Negative predictive value.

Similar to previous studies, our study confirmed that
not all enlarged or hypermetabolic LNs in cancer patients
are malignant (11,16–19). Of note in the present study are
the low specificity (29.4%) and PPV (42.8%) of FDG PETCT, which need to be discussed. Özgül et al. found that the
diagnostic sensitivity, specificity, PPV, NPV, and accuracy
of PET-CT scan based on the number of patients were
94.7%, 35.7%, 66.6%, 83.3%, and 69.6%, respectively (16).
Song et al. investigated the diagnostic value of EBUS-TBNA
and PET-CT in patients with extrapulmonary malignancy.
They reported that PET-CT specificity and PPV were both
89%, which was higher than in our study (17). However,
it should be noted that FDG is not a cancer-specific
diagnostic method; thus, false positive findings in benign
diseases have been reported (29,30). Infectious diseases
(mycobacterial, fungal, bacterial infection), sarcoidosis,
radiation pneumonitis, and postoperative surgical
conditions have shown intense uptake on PET scans (30).
In addition, pneumoconiosis, such as anthracosis, shows
hypermetabolic activity in FDG PET-CT. In developing
countries like ours, anthracosis may be another cause of
mediastinal lymphadenopathy (31). Our country, Turkey,
is one of the countries where granulomatous diseases such
as sarcoidosis and tuberculosis are common. In addition,
anthracosis associated with biomass exposure or intense
smoking is also not rare and should not be forgotten in

the differential diagnosis of enlarged hypermetabolic
lymph nodes. Therefore, histopathologic confirmation
for mediastinal or hilar lymphadenopathy is mandatory
in patients with proven or suspected extrapulmonary
malignancy, because reliance solely on radiographic
findings is insufficient for making an accurate clinical
diagnosis. In the present study, we had mostly benign
diseases; this caused false positive FDG uptake in PET-CT,
which led to a low specificity and a PPV.
There are some limitations of our study. The first
major limitation is that this study was a retrospective
study performed on a small number of patients from a
single center. Second, our population was heterogeneous
regarding types of malignancies and the locations of the
lymphadenopathy. Benign EBUS-TBNA results were not
confirmed with mediastinoscopy. However, the study’s
strength was that all cases (except 2) were followed
clinically and radiologically for at least 6 months.
In conclusion, EBUS-TBNA is a simple, safe,
minimally invasive, and accurate procedure for the
diagnosis of thoracic lymph node metastases in patients
with a known extrapulmonary malignancy. Our findings
lead us to recommend the use of EBUS-TBNA as an initial
diagnostic technique in these patients. Nevertheless, due
to the possibility of underdiagnosis, an invasive technique
is indicated when the results are negative.
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